Tracers / [90Y]Y-90-NM600

[90Y]Y-90-NM600

Also written as Y-90-NM600

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: NM600 (alkylphosphocholine analog)
Target / mechanism: —
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	SPE	—	>95%	NM600 Archeus Technologies	38663936 2024 J Immunother Cancer

Need this precursor?We can point you to suppliers for [90Y]Y-90-NM600, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38663936: 'Clinical grade 90YCl3 and NM600 were obtained from PerkinElmer (Shelton, CT) and Archeus Technologies (Madison, WI) respectively.'.